Refine by
Respiratory Virus Articles & Analysis
26 news found
That’s because COVID-19 spreads through respiratory droplets made when an infected person coughs, sneezes, or talks. ...
ByZeptive
[i] The paper, “Translational feasibility and efficacy of nasal photodynamic disinfection of SARS-CoV-2”, reports that 90% of patient samples showed decreased viral infectivity, with 70% showing no detectable virus after a single 5-minute treatment. The Canadian research team commented, “These promising results indicate the potential of photodisinfection as a ...
To see video, please click here This study, which enrolled 282 patients presenting to the Emergency Department (ED) with respiratory symptoms early in the COVID-19 pandemic, aimed to assess the IntelliSep Index (ISI) as a tool for risk stratification of patients with suspected infection presenting to the ED. The study reports the performance of this tool as a means to stratify ...
The company also provided the outlook for 2022 across its pipeline of allogeneic, off-the-shelf, virus-specific T cell (VST) therapies for immunocompromised patients, including its lead product posoleucel, an investigational VST in development for the treatment and prevention of infections and diseases caused by six common devastating viruses – adenovirus (AdV), BK ...
ByKalaris
Many RNA viruses need to activate this pathway to ensure their replication, such as influenza viruses[xii], hantaviruses[xiii], or the respiratory syncytial virus (RSV)[xiii] , and also coronaviruses[xiii] , including SARS-CoV-2. Zapnometinib inhibits the cellular MEK (MAPK/ERK kinase), blocking the formation of functional virus particles in the ...
This study is the second Phase 3 registrational study of posoleucel, following the initiation of the Phase 3 study for the treatment of virus-associated HC last year. Separately, the company also announced the initiation of a Phase 1/2 clinical trial (NCT04933968) of ALVR106, its investigational, allogeneic, off-the-shelf, multi-VST therapy for the treatment of infections caused ...
ByKalaris
This route mimics the natural infection pathway of the respiratory virus COVID-19 and may create additional benefits through generating mucosal immunity. ...
ByAerogen
The Viromed Group, based in Pinneberg near Hamburg, has been producing disinfection devices with the aid of plasmas and ionization for professional use in hospitals and practices for over 15 years and is recommended as the only manufacturer by the German Association of Pneumologists and Respiratory Medicine. Viromed commissioned SARS virus studies in security ...
The funding will accelerate the launch and broad market availability of the AscencioDx™ molecular diagnostic platform for the detection of RNA indicative of the SARS-CoV-2 / COVID-19 virus. Currently in clinical trials in the U.S., Anavasi expects to file its submission to the U.S. ...
The mucosal immune response is the first line of defense against respiratory viruses, providing fast-acting protection at the primary site of exposure. ...
The data confirm the potential of V-306 for prophylaxis against Respiratory Syncytial Virus (RSV) infection, possibly using a convenient needle-free method of vaccination. ...
· No vaccine is currently approved to protect against respiratory syncytial virus (RSV) · RSV is the leading cause of infant hospitalization in the United States and is considered the “missing” pediatric vaccine · Previous clinical data in seropositive adult and pediatric participants showed MV-012-968 was well-tolerated, ...
While circulating antibodies are important for preventing serious lung disease, mucosal antibodies are important for blocking infection and transmission of respiratory viruses. “Compared to injected vaccines, intranasal vaccines have greater potential to stop the transmission of SARS-CoV-2,” said Martin Moore, Ph.D., CEO and Cofounder of Meissa. ...
Beyond COVID-19 testing, Mesa Biotech's existing platform includes tests for flu, respiratory syncytial virus (RSV), and Strep A. "The Accula System complements our existing offerings and immediately provides our clinical customers with more options and flexibility for COVID-19 testing. ...
In fact, 75% of emerging diseases are zoonotic—and the ever-present risk that one of these strains may evolve into the next global pandemic increases as climate change, habitat encroachment, overpopulation and urbanization continue to alter our interaction with the natural world. SARS-CoV-2 (the virus that causes COVID-19) has an average mortality rate that is actually ...
- The randomized, double-blind, placebo-controlled challenge study is designed to evaluate safety and prophylactic efficacy of MV-012-968 against symptomatic respiratory syncytial virus (RSV) - Previous clinical data shows MV-012-968 is well-tolerated, heavily attenuated, and induces an RSV-specific mucosal IgA response in healthy seropositive adults and ...
Mesa Biotech has developed and commercialized a PCR-based rapid point-of-care testing platform available for detecting infectious diseases including SARS-CoV-2, Influenza A and B, respiratory syncytial virus (RSV) and Strep A. Mesa Biotech's patented technology expands the availability of gold standard nucleic acid PCR amplification to point-of-care diagnostics. ...
Thermo Fisher Scientific announces CE-marking of its TaqPath COVID-19, Flu A/B, RSV Combo Kit for the in vitro diagnosis of SARS-CoV-2, influenza A/B and respiratory syncytial virus (RSV) A/B infections. Using the new kit, laboratories can now can run a single test for SARS-CoV-2, influenza (flu) A/B, and RSV to detect and differentiate between diseases that ...
The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or Influenza B and/or Respiratory ...
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, announced today the completion of initial vaccination of the first dose cohort in the Phase 1 healthy volunteer study of V-306, its candidate vaccine for prophylaxis of RSV (Respiratory ...